Keywords: genentech/biogen, idec, rituxan, linked, death, ra, patient

Genentech/Biogen Idec's Rituxan linked to death of RA patient due to PML

Article | 22 September 2008

Print This

US biotechnology giant Genentech has warned doctors that its rheumatoid arthritis drug Rituxan (rituximab) may cause a rare brain disease.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in